文献速递泌尿生殖MRUS

前列腺癌:基于活检前磁共振成像的改良经直肠超声引导12针联合活检(靶向加系统活检)的诊断效能

Prostate cancer: diagnostic yield of modified transrectal ultrasound-guided twelve-core combined biopsy (targeted plus systematic biopsies) using prebiopsy magnetic resonance imaging.
PubMed 文献 · Abdom Radiol (NY) · 2021-06-28

这项回顾性研究纳入130例PI-RADS≥3且接受改良经直肠超声引导12针联合活检(认知融合靶向3-6针加系统活检)的患者,以ISUP≥2定义临床显著前列腺癌。靶向活检、系统活检和联合活检的临床显著前列腺癌检出率分别为47.7%、29.2%和52.3%;6例(4.6%)仅由系统活检检出,18例(13.8%)系统活检ISUP分级高于靶向活检,11例(8.5%)系统活检在靶向活检对侧外周带检出临床显著前列腺癌。作者认为该改良联合活检方案似乎可行,可能减少适合联合活检患者的穿刺针数。

要点

  • 联合活检临床显著前列腺癌检出率52.3%,高于靶向活检47.7%和系统活检29.2%。
  • 6例(4.6%)临床显著前列腺癌仅由系统活检检出,靶向活检存在漏诊。
  • 18例(13.8%)系统活检ISUP分级高于靶向活检,11例(8.5%)在对侧外周带检出临床显著前列腺癌。

核心结论

  • 基于活检前磁共振成像的改良经直肠超声引导12针联合活检似乎可行,可能减少适合联合活检患者的穿刺总针数。

研究设计与样本

  • 回顾性研究,纳入130例连续患者,均因PI-RADS≥3病灶接受改良经直肠超声引导12针联合活检并使用认知融合。

诊断标准与关键数值

  • 临床显著前列腺癌定义为国际泌尿病理学会(ISUP)分级≥2的癌。

临床应用与阅片要点

  • 联合活检中系统活检可检出靶向活检漏诊的临床显著前列腺癌(6例,4.6%)、更高ISUP分级癌(18例,13.8%)及靶向活检对侧外周带的临床显著前列腺癌(11例,8.5%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: This study aimed to analyze the diagnostic yield of modified transrectal ultrasound (TRUS)-guided 12-core combined biopsy (CB) using prebiopsy magnetic resonance imaging (MRI) for detecting clinically significant prostate cancer (csPCa).

METHODS: This retrospective study included 130 consecutive patients who underwent modified TRUS-guided 12-core CB using cognitive fusion for lesions of Prostate Imaging-Reporting and Data System (PI-RADS) category ≥ 3. The 12-core CB comprised 3-6-core targeted biopsy (TB) and systematic biopsy (SB). For SB, tissue sampling in TB regions was omitted, and 3-core sampling (i.e., apex, mid, and base) in the contralateral peripheral zone of TB was mandatory. csPCa was defined as International Society of Urological Pathology (ISUP) grade ≥ 2 cancer. The per-patient cancer detection rates (CDRs) according to biopsy type or PI-RADS category were investigated.

RESULTS: The CDRs of TB, SB, and CB for csPCa were 47.7% (62/130 patients), 29.2% (38/130), and 52.3% (68/130), respectively. For csPCa, the CDRs of TB and CB according to PI-RADS categories of 3, 4, or 5 were 25.0% (8/32) and 31.3% (10/32), 41.2% (28/68) and 45.6% (31/68), or 86.7% (26/30) and 90.0% (27/30), respectively. In 6 (4.6%) patients, csPCa was detected only by SB. In 18 (13.8%) patients, SB detected PCa of a higher ISUP grade than TB. In 11 (8.5%) patients, SB detected csPCa at contralateral peripheral zone of TB.

CONCLUSION: Modified TRUS-guided 12-core CB using prebiopsy MRI seems to be feasible. It may reduce total biopsy cores in patients who are suitable for CB based on prebiopsy MRI findings.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Song C, Park SY. Prostate cancer: diagnostic yield of modified transrectal ultrasound-guided twelve-core combined biopsy (targeted plus systematic biopsies) using prebiopsy magnetic resonance imaging. Abdom Radiol (NY). 2021. PMID: 34181040. doi:10.1007/s00261-021-03179-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。